456 related articles for article (PubMed ID: 18776926)
1. The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT.
McCann S; Schwenkglenks M; Bacon P; Einsele H; D'Addio A; Maertens J; Niederwieser D; Rabitsch W; Roosaar A; Ruutu T; Schouten H; Stone R; Vorkurka S; Quinn B; Blijlevens N;
Bone Marrow Transplant; 2009 Jan; 43(2):141-7. PubMed ID: 18776926
[TBL] [Abstract][Full Text] [Related]
2. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.
Blijlevens N; Schwenkglenks M; Bacon P; D'Addio A; Einsele H; Maertens J; Niederwieser D; Rabitsch W; Roosaar A; Ruutu T; Schouten H; Stone R; Vokurka S; Quinn B; McCann S;
J Clin Oncol; 2008 Mar; 26(9):1519-25. PubMed ID: 18268357
[TBL] [Abstract][Full Text] [Related]
3. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
[TBL] [Abstract][Full Text] [Related]
4. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
Costa LJ; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Litzow MR; Ansell SM
Br J Haematol; 2008 Oct; 143(2):268-73. PubMed ID: 18699848
[TBL] [Abstract][Full Text] [Related]
5. A phase Ib clinical trial of PV701, a milk-derived protein extract, for the prevention and treatment of oral mucositis in patients undergoing high-dose BEAM chemotherapy.
Prince HM; Regester G; Gates P; Jablonskis L; Seymour JF; Lillie K; West R; Wolf M; Januszewicz H; Belford D
Biol Blood Marrow Transplant; 2005 Jul; 11(7):512-20. PubMed ID: 15983551
[TBL] [Abstract][Full Text] [Related]
6. The risk factors for oral mucositis and the effect of cryotherapy in patients after the BEAM and HD-l-PAM 200 mg/m(2) autologous hematopoietic stem cell transplantation.
Vokurka S; Bystricka E; Scudlova J; Mazur E; Visokaiova M; Vasilieva E; Brandejsova R; Chvojkova I; Vrabcova M; Vitkova J; Mjartanova D; Vodickova M; Bockova J; Streinerova K
Eur J Oncol Nurs; 2011 Dec; 15(5):508-12. PubMed ID: 21310656
[TBL] [Abstract][Full Text] [Related]
7. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
Wang EH; Chen YA; Corringham S; Bashey A; Holman P; Ball ED; Carrier E
Bone Marrow Transplant; 2004 Oct; 34(7):581-7. PubMed ID: 15273714
[TBL] [Abstract][Full Text] [Related]
8. Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option.
Seropian S; Nadkarni R; Jillella AP; Salloum E; Burtness B; Hu GL; Zelterman D; Cooper DL
Bone Marrow Transplant; 1999 Mar; 23(6):599-605. PubMed ID: 10217191
[TBL] [Abstract][Full Text] [Related]
9. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.
Jo JC; Kang BW; Jang G; Sym SJ; Lee SS; Koo JE; Kim JW; Kim S; Huh J; Suh C
Ann Hematol; 2008 Jan; 87(1):43-8. PubMed ID: 17710401
[TBL] [Abstract][Full Text] [Related]
10. Efficiency of supersaturated calcium phosphate mouth rinse treatment in patients receiving high-dose melphalan or BEAM prior to autologous blood stem cell transplantation: a single-center experience.
Waśko-Grabowska A; Rzepecki P; Oborska S; Barzał J; Gawroński K; Młot B; Szczylik C
Transplant Proc; 2011 Oct; 43(8):3111-3. PubMed ID: 21996239
[TBL] [Abstract][Full Text] [Related]
11. Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma.
Wildes TM; Augustin KM; Sempek D; Zhang QJ; Vij R; Dipersio JF; Devine SM
Biol Blood Marrow Transplant; 2008 Jul; 14(7):840-6. PubMed ID: 18541205
[TBL] [Abstract][Full Text] [Related]
12. Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol.
Jantunen E; Mahlamäki E; Nousiainen T
Bone Marrow Transplant; 2000 Oct; 26(7):737-41. PubMed ID: 11042654
[TBL] [Abstract][Full Text] [Related]
13. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity.
Kim JE; Lee DH; Yoo C; Kim S; Kim SW; Lee JS; Park CJ; Huh J; Suh C
Leuk Res; 2011 Feb; 35(2):183-7. PubMed ID: 20684990
[TBL] [Abstract][Full Text] [Related]
14. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study.
Musso M; Scalone R; Marcacci G; Lanza F; Di Renzo N; Cascavilla N; Di Bartolomeo P; Crescimanno A; Perrone T; Pinto A
Bone Marrow Transplant; 2010 Jul; 45(7):1147-53. PubMed ID: 19898504
[TBL] [Abstract][Full Text] [Related]
15. Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
Clavio M; Garrone A; Pierri I; Michelis GL; Balocco M; Albarello A; Varaldo R; Canepa P; Miglino M; Ballerini F; Canepa L; Gobbi M
Oncol Rep; 2005 Oct; 14(4):933-40. PubMed ID: 16142354
[TBL] [Abstract][Full Text] [Related]
16. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
Grazziutti ML; Dong L; Miceli MH; Krishna SG; Kiwan E; Syed N; Fassas A; van Rhee F; Klaus H; Barlogie B; Anaissie EJ
Bone Marrow Transplant; 2006 Oct; 38(7):501-6. PubMed ID: 16980998
[TBL] [Abstract][Full Text] [Related]
17. Comparative pharmacokinetic study of high-dose etoposide and etoposide phosphate in patients with lymphoid malignancy receiving autologous stem cell transplantation.
Dorr RT; Briggs A; Kintzel P; Meyers R; Chow HH; List A
Bone Marrow Transplant; 2003 Apr; 31(8):643-9. PubMed ID: 12692603
[TBL] [Abstract][Full Text] [Related]
18. Keratinocyte growth factor is effective in the prevention of intestinal mucositis in patients with hematological malignancies treated with high-dose chemotherapy and autologous hematopoietic SCT: a video-capsule endoscopy study.
Tsirigotis P; Triantafyllou K; Girkas K; Giannopoulou V; Ioannidou E; Chondropoulos S; Kalli T; Papaxoinis G; Pappa V; Papageorgiou E; Economopoulos T; Ladas SD; Dervenoulas J
Bone Marrow Transplant; 2008 Sep; 42(5):337-43. PubMed ID: 18560408
[TBL] [Abstract][Full Text] [Related]
19. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma.
Thieblemont C; Dumontet C; Saad H; Roch N; Bouafia F; Arnaud P; Hequet O; Espinouse D; Salles G; Roy P; Eljaafari-Corbin A; Du Manoir-Baumgarten C; Coiffier B
Bone Marrow Transplant; 2002 Dec; 30(11):769-75. PubMed ID: 12439700
[TBL] [Abstract][Full Text] [Related]
20. [Transdermal fentanyl in treating severe painful mucositis caused by autologous hematopoietic stem cell transplantation].
Huang HQ; Cai QQ; Lin XB; Wang BF; Bu Q; Gao Y; Peng YL
Ai Zheng; 2007 Apr; 26(4):390-3. PubMed ID: 17430658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
